We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Royalty Rate Set In Boston, Cordis Stent Spat

Law360 (April 13, 2009, 12:00 AM EDT) -- Resolving all remaining issues in a seven-year dispute over stent patents, a federal judge has ruled that Boston Scientific Corp. must pay a 5.1 percent royalty rate on its sales of...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.